Literature DB >> 15545053

Circulating levels of cyclooxygenase metabolites in experimental Trypanosoma cruzi infections.

Rita L Cardoni1, María Inés Antúnez.   

Abstract

Trypanosoma cruzi induces inflammatory reactions in several tissues. The production of prostaglandin F2alpha, 6-keto-prostaglandin F1alpha and thromboxane B2, known to regulate the immune response and to participate in inflammatory reactions, was studied in mice experimentally infected with T. cruzi. The generation of nitric oxide (NO), which could be regulated by cyclooxygenase metabolites, was also evaluated. In the acute infection the extension of inflammatory infiltrates in skeletal muscle as well as the circulating levels of cyclooxygenase metabolites and NO were higher in resistant C3H mice than in susceptible BALB/c mice. In addition, the spontaneous release of NO by spleen cells increased earlier in the C3H mouse strain. In the chronic infections, the tissue inflammatory reaction was still prominent in both groups of mice, but a moderate increase of thromboxane B2 concentration and in NO released by spleen cells was observed only in C3H mice. This comparative study shows that these mediators could be mainly related to protective mechanisms in the acute phase, but seem not to be involved in its maintenance in the chronic T. cruzi infections.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15545053      PMCID: PMC1781569          DOI: 10.1080/09637480400003022

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  37 in total

1.  Interleukin-12-mediated resistance to Trypanosoma cruzi is dependent on tumor necrosis factor alpha and gamma interferon.

Authors:  C A Hunter; T Slifer; F Araujo
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  LPS-dependent cyclooxygenase-2 induction in human monocytes is down-regulated by IL-13, but not by IFN-gamma.

Authors:  T Endo; F Ogushi; S Sone
Journal:  J Immunol       Date:  1996-03-15       Impact factor: 5.422

3.  Detection of live Trypanosoma cruzi in tissues of infected mice by using histochemical stain for beta-galactosidase.

Authors:  F S Buckner; A J Wilson; W C Van Voorhis
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

4.  Defective nitric oxide effector functions lead to extreme susceptibility of Trypanosoma cruzi-infected mice deficient in gamma interferon receptor or inducible nitric oxide synthase.

Authors:  C Hölscher; G Köhler; U Müller; H Mossmann; G A Schaub; F Brombacher
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

5.  Prostaglandins mediate suppression of lymphocyte proliferation and cytokine synthesis in acute Trypanosoma cruzi infection.

Authors:  P Pinge-Filho; C E Tadokoro; I A Abrahamsohn
Journal:  Cell Immunol       Date:  1999-04-10       Impact factor: 4.868

6.  Trypanosoma cruzi induces strong IL-12 and IL-18 gene expression in vivo: correlation with interferon-gamma (IFN-gamma) production.

Authors:  C Meyer Zum Büschenfelde; S Cramer; C Trumpfheller; B Fleischer; S Frosch
Journal:  Clin Exp Immunol       Date:  1997-12       Impact factor: 4.330

7.  Release of reactive oxygen species by phagocytic cells in response to live parasites in mice infected with Trypanosoma cruzi.

Authors:  R L Cardoni; M I Antunez; C Morales; I R Nantes
Journal:  Am J Trop Med Hyg       Date:  1997-03       Impact factor: 2.345

8.  Prostaglandin and nitric oxide regulate TNF-alpha production during Trypanosoma cruzi infection.

Authors:  M M Borges; J K Kloetzel; H F Andrade; C E Tadokoro; P Pinge-Filho; I Abrahamsohn
Journal:  Immunol Lett       Date:  1998-08       Impact factor: 3.685

9.  Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages.

Authors:  J S Silva; G N Vespa; M A Cardoso; J C Aliberti; F Q Cunha
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

10.  PGE2 involvement in experimental infection with Trypanosoma cruzi subpopulations.

Authors:  A M Celentano; G Gorelik; M E Solana; L Sterin-Borda; E Borda; S M González Cappa
Journal:  Prostaglandins       Date:  1995-03
View more
  14 in total

Review 1.  Bioactive lipids in Trypanosoma cruzi infection.

Authors:  Fabiana S Machado; Shankar Mukherjee; Louis M Weiss; Herbert B Tanowitz; Anthony W Ashton
Journal:  Adv Parasitol       Date:  2011       Impact factor: 3.870

2.  Combination Therapy Using Benznidazole and Aspirin during the Acute Phase of Experimental Chagas Disease Prevents Cardiovascular Dysfunction and Decreases Typical Cardiac Lesions in the Chronic Phase.

Authors:  Rito Santo Pereira; Aparecida Donizette Malvezi; Maria Isabel Lovo-Martins; Bruno Fernando Cruz Lucchetti; Jussevania Pereira Santos; Eliandro Reis Tavares; Waldiceu Aparecido Verri; Eduardo José de Almeida Araújo; Lucy Megumi Yamauchi; Sueli Fumie Yamada-Ogatta; Marli Cardoso Martins-Pinge; Phileno Pinge-Filho
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 3.  Perspectives on the Trypanosoma cruzi-host cell receptor interactions.

Authors:  Fernando Villalta; Julio Scharfstein; Anthony W Ashton; Kevin M Tyler; Fangxia Guan; Shankar Mukherjee; Maria F Lima; Sandra Alvarez; Louis M Weiss; Huan Huang; Fabiana S Machado; Herbert B Tanowitz
Journal:  Parasitol Res       Date:  2009-03-13       Impact factor: 2.289

4.  Identification of a functional prostanoid-like receptor in the protozoan parasite, Trypanosoma cruzi.

Authors:  Shankar Mukherjee; Nikaeta Sadekar; Anthony W Ashton; Huan Huang; David C Spray; Michael P Lisanti; Fabiana S Machado; Louis M Weiss; Herbert B Tanowitz
Journal:  Parasitol Res       Date:  2013-02-13       Impact factor: 2.289

5.  Aspirin treatment of mice infected with Trypanosoma cruzi and implications for the pathogenesis of Chagas disease.

Authors:  Shankar Mukherjee; Fabiana S Machado; Huang Huang; Helieh S Oz; Linda A Jelicks; Cibele M Prado; Wade Koba; Eugene J Fine; Dazhi Zhao; Stephen M Factor; J Elias Collado; Louis M Weiss; Herbert B Tanowitz; Anthony W Ashton
Journal:  PLoS One       Date:  2011-02-15       Impact factor: 3.240

6.  Role of cyclooxygenase-2 in Trypanosoma cruzi survival in the early stages of parasite host-cell interaction.

Authors:  Karen C M Moraes; Lívia F Diniz; Maria Terezinha Bahia
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-04       Impact factor: 2.743

7.  Aspirin modulates innate inflammatory response and inhibits the entry of Trypanosoma cruzi in mouse peritoneal macrophages.

Authors:  Aparecida Donizette Malvezi; Rosiane Valeriano da Silva; Carolina Panis; Lucy Megumi Yamauchi; Maria Isabel Lovo-Martins; Nagela Ghabdan Zanluqui; Vera Lúcia Hideko Tatakihara; Luiz Vicente Rizzo; Waldiceu A Verri; Marli Cardoso Martins-Pinge; Sueli Fumie Yamada-Ogatta; Phileno Pinge-Filho
Journal:  Mediators Inflamm       Date:  2014-06-19       Impact factor: 4.711

8.  Protective role of acetylsalicylic acid in experimental Trypanosoma cruzi infection: evidence of a 15-epi-lipoxin A₄-mediated effect.

Authors:  Alfredo Molina-Berríos; Carolina Campos-Estrada; Natalia Henriquez; Mario Faúndez; Gloria Torres; Christian Castillo; Sebastián Escanilla; Ulrike Kemmerling; Antonio Morello; Rodrigo A López-Muñoz; Juan D Maya
Journal:  PLoS Negl Trop Dis       Date:  2013-04-18

9.  Trypanosoma cruzi infection and endothelin-1 cooperatively activate pathogenic inflammatory pathways in cardiomyocytes.

Authors:  Ricardo S Corral; Néstor A Guerrero; Henar Cuervo; Núria Gironès; Manuel Fresno
Journal:  PLoS Negl Trop Dis       Date:  2013-02-07

10.  Cyclooxygenase-2 and Prostaglandin E2 Signaling through Prostaglandin Receptor EP-2 Favor the Development of Myocarditis during Acute Trypanosoma cruzi Infection.

Authors:  Néstor A Guerrero; Mercedes Camacho; Luis Vila; Miguel A Íñiguez; Carlos Chillón-Marinas; Henar Cuervo; Cristina Poveda; Manuel Fresno; Núria Gironès
Journal:  PLoS Negl Trop Dis       Date:  2015-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.